Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Wang

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Blood|April 15, 2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targetsKartik Sehgal, Rituparna Das, Lin Zhang, et al.
Leukemia & Lymphoma|July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
British Journal of Haematology|November 12, 2013
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexityAnita K Gandhi, Derek Mendy, Michelle Waldman, et al.
Blood|January 25, 2020
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agentAlberto Risueño, Patrick R Hagner, Fadi Towfic, et al.
Nature Structural & Molecular Biology|August 11, 2014
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogsPhilip P Chamberlain, Antonia Lopez-Girona, Karen Miller, et al.
Nature Chemical Biology|September 8, 2018
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrateMary E Matyskiela, Suzana Couto, Xinde Zheng, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Haematologica|March 17, 2018
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Suzana Couto, et al.
Blood|May 24, 2015
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCLPatrick R Hagner, Hon-Wah Man, Celia Fontanillo, et al.
Blood|January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifierCecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Blood|April 15, 2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targetsKartik Sehgal, Rituparna Das, Lin Zhang, et al.
Leukemia & Lymphoma|July 15, 2021
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, et al.
British Journal of Haematology|November 12, 2013
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexityAnita K Gandhi, Derek Mendy, Michelle Waldman, et al.
Blood|January 25, 2020
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agentAlberto Risueño, Patrick R Hagner, Fadi Towfic, et al.
Nature Structural & Molecular Biology|August 11, 2014
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogsPhilip P Chamberlain, Antonia Lopez-Girona, Karen Miller, et al.
Nature Chemical Biology|September 8, 2018
SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrateMary E Matyskiela, Suzana Couto, Xinde Zheng, et al.
Leukemia & Lymphoma|August 20, 2020
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myelomaOliver Van Oekelen, Samir Parekh, Hearn J Cho, et al.
Haematologica|March 17, 2018
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsLaurens E Franssen, Inger S Nijhof, Suzana Couto, et al.
Blood|May 24, 2015
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCLPatrick R Hagner, Hon-Wah Man, Celia Fontanillo, et al.
Blood|January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifierCecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Pageof 5